Recently, there has been a great deal of focus on the uses and risks of marijuana in the field of epilepsy. Epidiolex, a treatment of cannabidiol (CBD), recently gained FDA approval for the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome, two rare and severe forms of epilepsy. This is the first FDA-approved plant based treatment with greater than 98% CBD.
Unlike THC, one of the other components in marijuana, CBD does not cause the euphoria (the “high”) that comes from THC.
In this webinar, you will learn why CBD may be an effective treatment for certain types of epilepsy, what risks can be associated with CBD, and what the FDA approval of means for the future of epilepsy research and treatment.
Featured Presenter: Anup D. Patel, MD, is Section Chief of Pediatric Neurology at Nationwide Children’s and Associate Professor of Clinical Pediatrics and Neurology at The Ohio State University College of Medicine
This webinar is made possible thanks to the generous funding provided by Sunovion Pharmaceuticals.